- Home
- LEO vs KALV Comparison
LEO vs KALV Comparison
Compare LEO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- KALV
- Stock Information
- Founded
- LEO 1987
- KALV N/A
- Country
- LEO United States
- KALV United States
- Employees
- LEO N/A
- KALV N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- LEO Finance
- KALV Health Care
- Exchange
- LEO Nasdaq
- KALV Nasdaq
- Market Cap
- LEO 385.0M
- KALV 362.2M
- IPO Year
- LEO N/A
- KALV N/A
- Fundamental
- Price
- LEO $6.19
- KALV $8.30
- Analyst Decision
- LEO
- KALV Strong Buy
- Analyst Count
- LEO 0
- KALV 7
- Target Price
- LEO N/A
- KALV $27.00
- AVG Volume (30 Days)
- LEO 200.2K
- KALV 350.1K
- Earning Date
- LEO 01-01-0001
- KALV 03-10-2025
- Dividend Yield
- LEO 4.01%
- KALV N/A
- EPS Growth
- LEO N/A
- KALV N/A
- EPS
- LEO 0.04
- KALV N/A
- Revenue
- LEO N/A
- KALV N/A
- Revenue This Year
- LEO N/A
- KALV N/A
- Revenue Next Year
- LEO N/A
- KALV N/A
- P/E Ratio
- LEO $152.00
- KALV N/A
- Revenue Growth
- LEO N/A
- KALV N/A
- 52 Week Low
- LEO $4.98
- KALV $7.30
- 52 Week High
- LEO $6.50
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- LEO 53.48
- KALV 45.86
- Support Level
- LEO $5.99
- KALV $7.30
- Resistance Level
- LEO $6.18
- KALV $9.16
- Average True Range (ATR)
- LEO 0.06
- KALV 0.40
- MACD
- LEO 0.02
- KALV 0.02
- Stochastic Oscillator
- LEO 82.00
- KALV 53.91
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.